NetworkNewsWire Editorial Coverage: When it comes to cancer – a
disease that has been referred to as the “modern plague” - any
positive developments are good news indeed. In the ongoing battle
against cancer, companies like TapImmune, Inc. (TPIV)
(TPIV
Profile), Anavex Life
Sciences Corp. (AVXL), Propanc Health Group
Corporation (PPCH), Aquinox Pharmaceutical, Inc.
(AQXP) and Bellicum Pharmaceuticals, Inc.
(BLCM) are working hard to bring even more good news to
cancer patients and their families.
There was both good and bad news in the United States
Government’s latest Annual Report to the Nation on the Status of
Cancer (1), which covers the time period spanning
1975-2014. The good news: cancer death rates continue to decrease
in men, women and children for all major ethnic groups; the overall
rates of new cancers have decreased in men and stabilized in women;
and five-year survival rates have improved for most—but not
all—common types of cancer, including both early- and late-stage
disease. The bad news: death rates have increased for liver,
pancreas and brain cancers in men and for liver and uterine cancers
in women.
Fewer bad tidings and many more good are the aim of various
companies engaged in finding and developing new and innovative
means of treating cancer.
Some exciting cancer therapy advancements come from TapImmune, Inc. (TPIV), a leading
immuno-oncology company that provides pioneering T-cell vaccines
and novel immunotherapy platforms. TapImmune’s immunotherapies take
the unique approach of targeting both metastatic disease and
tumors. The primary cause of death among cancer patients is not the
primary tumor but metastatic disease, or the spreading of cancer to
untreatable areas of the body. TapImmune’s therapies have advanced
beyond the abilities of earlier vaccine approaches by treating both
tumors and metastatic diseases, and TapImmune’s work is further
distinguished by its approach of activating a patient’s own immune
system in fighting cancer. While the idea of enlisting the body’s
immune system to combat cancer is not a new one, recent and
dramatic breakthroughs by companies like TapImmune have brought
this concept to the forefront in an exciting way.
TapImmune’s next-generation technology is able to standalone as
a powerful therapy or be combined with other immunotherapies. The
company is currently developing two vaccines that merge proprietary
peptide antigen sets designed to invoke both killer T-cell (CD8)
and helper T-cell (CD4) immune responses against specific proteins
present on the surface of most target tumor cells. The naturally
processed antigens in these vaccines are derived from human immune
responses that are recognized by over 85 percent of the population.
This enables TapImmune to direct a uniquely strong and durable
anti-tumor immune response across a broader patient population.
Other companies in the oncology field lag far behind TapImmune,
developing immune-modulating technologies that prompt only CD4
T-cell response, only CD8 T-cell response, or none at all.
The company is currently advancing its two clinical-stage T-cell
vaccine candidates in multiple phase II and phase Ib/IIa clinical
trials for treating ovarian and breast cancers, both of which are
typically resistant to immunotherapies. Included are ovarian cancer
programs that will benefit from FDA Fast Track and Orphan Disease
Designation. TapImmune is collaborating with industry and clinical
leaders like the Mayo Clinic, AstraZeneca and the Memorial Sloan
Kettering Cancer Center.
Clinical-stage biopharmaceutical company Anavex Life
Sciences (AVXL) is engaged in developing differentiated
therapeutics to treat a variety of diseases, including cancer. The
company is exploring the approach of using sigma receptors as
targets for therapeutics to combat disease. Anavex has found that
when sigma receptors are bound by the appropriate ligands, they
influence the function of multiple biochemical signals involved in
pathogenesis, or the origin of disease. The company’s pipeline
includes compounds in varying stages of preclinical study for the
treatment of melanoma, pancreatic cancer, prostate cancer, colon
cancer and ovarian cancer.
Propanc Health Group (PPCH), a
development-stage health care company, is focused on developing new
and proprietary treatments for cancer patients who are suffering
from solid tumors like pancreatic, ovarian and colorectal cancers.
Working with scientific and oncology consultants, Propanc has
developed a rational, composite formulation of anti-cancer
compounds that work together to exert various effects designed to
control or prevent the recurrence and spread of tumors. The
company’s leading products are variations on its novel formulation
and involve or employ proenzymes. The company’s long-term therapy
is based on a pancreatic proenzyme formulation to suppress tumor
recurrence and metastasis, while PRP, its lead candidate, controls
cancer cell migration, impedes tumor blood vessel formation and
triggers cell death.
Clinical-stage biopharmaceutical company Aquinox
Pharmaceutical (AQXP) is also focused on the discovery and
development of targeted therapeutics in immuno-oncology disease
areas. While the company’s chief focus is currently
anti-inflammatory product candidates, its longer-term strategy is
to broaden development activities for its lead product candidate,
AXQ-1125, for the treatment of cancer.
The approach of clinical-stage biopharmaceutical company
Bellicum Pharmaceuticals (BLCM) is developing
novel stem cell transplant, TCR and CAR T cell therapies. Operating
on the belief that cellular control is the key to safer, more
effective cell therapies, the company’s product candidates
incorporate molecular switches that are designed to allow the
activation or elimination of therapeutic cells within the body. The
focus of Bellicum Pharmaceuticals is discovering and developing
cellular immunotherapies for hematological cancers, solid tumors
and orphan inherited blood diseases.
As advancements continue in the fight against cancer, these
companies continue their efforts to develop new methods for
combating the disease and increase instances of good news for
cancer patients and their loved ones.
Editorial Sources:
(1) Cancer.gov: http://nnw.fm/9uSBp
For more information on TapImmune visit: TapImmune,
Inc. or www.Tapimmune.com
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides to
users (1) access to our news aggregation and syndication servers,
(2) enhanced press release services, and (3) a full array of social
communication solutions. As a multifaceted financial news and
content distribution company with an extensive team of contributing
journalists and writers, NNW is uniquely positioned to best serve
private and public companies that desire to reach a wide audience
of investors, consumers, journalists and the general public. NNW
has an ever-growing distribution network of more than 5,000 key
syndication outlets across the country. By cutting through the
overload of information in today's market, NNW brings its clients
unparalleled visibility, recognition and brand awareness. NNW is
where news, content and information converge.
http://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. FN Media
Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through
multiple online media channels. FNM is NOT affiliated with NNW or
any company mentioned herein. The commentary, views and opinions
expressed in this release by NNW are solely those of NNW and are
not shared by and do not reflect in any manner the views or
opinions of FNM. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW and FNM for any
investment decisions by their readers or subscribers. NNW and FNM
and their respective affiliated companies are a news dissemination
and financial marketing solutions provider and are NOT registered
broker-dealers/analysts/investment advisers, hold no investment
licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, FNM, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer's filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer's securities, including, but not
limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS
RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW and FNM undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Propanc Biopharma (PK) (USOTC:PPCB)
Historical Stock Chart
From Dec 2024 to Jan 2025
Propanc Biopharma (PK) (USOTC:PPCB)
Historical Stock Chart
From Jan 2024 to Jan 2025
